Citation Impact
Citing Papers
Serial measurement of M. tuberculosis in blood from critically-ill patients with HIV-associated tuberculosis
2022 StandoutNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
2020 Standout
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development
2015
Safety Review: Squalene and Thimerosal in Vaccines
2010
Development and regulation of monoclonal antibody products: Challenges and opportunities
2005
Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study
2016
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
ETHANOL INDUCES HIGHER BEC IN CB1 CANNABINOID RECEPTOR KNOCKOUT MICE WHILE DECREASING ETHANOL PREFERENCE
2004
Encoded libraries of chemically modified peptides
2015 StandoutNobel
Crohn's disease
2012 Standout
COVID-19: A promising cure for the global panic
2020 Standout
Hepatocellular carcinoma
2021 Standout
Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse.
1998
Engineering interferons and interleukins for cancer immunotherapy
2022
Delivery technologies for cancer immunotherapy
2019 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
2014 StandoutNobel
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
2011
Pharmacological characterization of PF‐00547659, an anti‐human MAdCAM monoclonal antibody
2009
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
2010
Therapeutic targeting of the angiopoietin–TIE pathway
2017
Bispecific antibodies for cancer therapy: A review
2017
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
2018
Squalene Selectively Protects Mouse Bone Marrow Progenitors Against Cisplatin and Carboplatin-Induced Cytotoxicity In Vivo Without Protecting Tumor Growth
2008
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The past, present and future of anti-malarial medicines
2019
Control of Neglected Tropical Diseases
2007 Standout
Drug discovery and development for neglected parasitic diseases
2006
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Drugs derived from phage display
2013
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology
2000 Standout
Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.
2017
Combination therapy in combating cancer
2017 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies
2016
Generation of Anti-trypanosomal Agents through Concise Synthesis and Structural Diversification of Sesquiterpene Analogues
2011 StandoutNobel
Works of Benjamin Wu being referenced
Investigation of the Mechanism of Clearance of AMG 386, a Selective Angiopoietin-1/2 Neutralizing Peptibody, in Splenectomized, Nephrectomized, and FcRn Knockout Rodent Models
2011
Analysis of 2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl)nortropane in rat plasma
2001
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody
2004
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
2016
Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed
2002
A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
2013
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
2019
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
2013
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
2014
Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
2015
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours
2014
Pharmacokinetics of the Antimalarial Drug, AQ-13, in Rats and Cynomolgus Macaques
2004
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
2015
The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab
2006
[Effect of acupuncture on interleukin-2 level and NK cell immunoactivity of peripheral blood of malignant tumor patients].
1994
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
2010